Search Results - "FIJNHEER, R."

Cold case: COVID-19-triggered type 1 cryoglobulinemia by van Gils, L.A.J. (Luuk), Corsten, M.F. (Maarten), Koelman, C.A. (Carin), Bosma, R.J. (Renate), Fijnheer, R. (Rob), Mulder, A.H.L. (Leontine), Regelink, J.C. (Josien)

“…A 42-year-old male was referred to the internal medicine department because of renal failure and persistent malaise after a recent SARS-CoV-2 infection. Blood…”
Get full text

Haemostatic differences between SARS-CoV-2 PCR-positive and negative patients at the time of hospital admission by de Laat, B, Traets, M J M, De Laat-Kremers, R W M, Verweij, S P, Ninivaggi, M, Jong, E, Huskens, D, Blok, B A, Remme, G C P, Miszta, A, Nijhuis, R H T, Herder, G J M, Fijnheer, R, Roest, M, Fiolet, A T L, Remijn, J A

“…Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with thrombosis. We conducted a…”
Get full text

Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? by Adams, H.J.A., Kwee, T.C., de Keizer, B., Fijnheer, R., de Klerk, J.M.H., Littooij, A.S., Nievelstein, R.A.J.

“…This study aimed to systematically review and meta-analyze published data on the diagnostic performance of 18F-fluoro-2-deoxy-d-glucose positron emission…”
Get full text

Identification of N‐linked glycosylation and putative O‐fucosylation, C‐mannosylation sites in plasma derived ADAMTS13 by Sorvillo, N., Kaijen, P. H., Matsumoto, M., Fujimura, Y., Zwaan, C., Verbij, F. C., Pos, W., Fijnheer, R., Voorberg, J., Meijer, A. B.

“…Summary Background Acquired deficiency of ADAMTS13 causes a rare and life‐threatening disorder called thrombotic thrombocytopenic purpura (TTP). Several…”
Get full text

New therapeutic options for immune thrombocytopenia by SCHIPPERUS, M, FIJNHEER, R

“…Understanding of the mechanisms and aetiology of immune thrombocytopenia (ITP) has progressed significantly in recent years. It is now recognised to be an…”
Get full text

Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome by HULSTEIN, J. J. J., VAN RUNNARD HEIMEL, P. J., FRANX, A., LENTING, P. J., BRUINSE, H. W., SILENCE, K., DE GROOT, PH. G., FIJNHEER, R.

“…Background: HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome is a severe complication of pre‐eclampsia in pregnancy, characterized by…”
Get full text

Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain by POS, Wouter, SORVILLO, Nicoletta, FIJNHEER, Rob, FEYS, Hendrik B, KAIJEN, Paul H. P, VIDARSSON, Gestur, VOORBERG, Jan

“…The majority of patients diagnosed with thrombotic thrombocytopenic purpura have autoantibodies directed towards the spacer domain of ADAMTS13. In this study…”
Get full text

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura by Roose, Elien, Schelpe, An-Sofie, Tellier, Edwige, Sinkovits, György, Joly, Bérangère S., Dekimpe, Charlotte, Kaplanski, Gilles, Le Besnerais, Maelle, Mancini, Ilaria, Falter, Tanja, Von Auer, Charis, Feys, Hendrik B., Reti, Marienn, Rossmann, Heidi, Vandenbulcke, Aline, Pareyn, Inge, Voorberg, Jan, Greinacher, Andreas, Benhamou, Ygal, Deckmyn, Hans, Fijnheer, Rob, Prohászka, Zoltan, Peyvandi, Flora, Lämmle, Bernhard, Coppo, Paul, De Meyer, Simon F., Veyradier, Agnès, Vanhoorelbeke, Karen

“…Recently, we showed that ADAMTS13 circulates in an open conformation during the acute phase of immune-mediated thrombotic thrombocytopenic purpura (iTTP)…”
Get full text

VH1‐69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura by POS, W., LUKEN, B. M., KREMER HOVINGA, J. A., TURENHOUT, E. A. M., SCHEIFLINGER, F., DONG, J.‐F., FIJNHEER, R., VOORBERG, J.

“…Background: Autoantibodies directed towards ADAMTS13 are present in the majority of patients with acquired thrombotic thrombocytopenic purpura (TTP). Analysis…”
Get full text

Splenectomy for the treatment of thrombotic thrombocytopenic purpura by Kappers‐Klunne, M. C., Wijermans, P., Fijnheer, R., Croockewit, A. J., Holt, B., Wolf, J. T. M., Löwenberg, B., Brand, A.

“…Summary Plasma exchange is the treatment of choice for patients with thrombotic thrombocytopenic purpura (TTP) and results in remission in >80% of the cases…”
Get full text

Agonist‐induced platelet reactivity correlates with bleeding in haemato‐oncological patients by Batman, B., Bladel, E. R., Hamersveld, M., Pasker‐de Jong, P. C. M., Korporaal, S. J. A., Urbanus, R. T., Roest, M., Boven, L. A., Fijnheer, R.

“…Background and objective Prophylactic platelet transfusions are administered to prevent bleeding in haemato‐oncological patients. However, bleeding still…”
Get full text

Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment by Minnema, M. C., Fijnheer, R., De Groot, P. G., Lokhorst, H. M.

“…Venous thromboembolism (VTE) is a major complication in patients with multiple myeloma (MM) during treatment with thalidomide combined with chemotherapy and/or…”
Get full text

P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B‐ALL IN ADULTS. A PHASE II HOVON TRIAL by Rijneveld, A., Gradowska, P., Bellido, M., Weerdt, O., Gadisseur, A., Deeren, D., Wagen, L., Jauw, Y., Fijnheer, R., Lammerren, D., Selleslag, D., Halkes, S., Biemond, B., Breems, D., Moors, I., Sluis, G., Bakkus, M., Homburg, C., Janda, V., Velden, V., Cornelissen, J.

Get full text

RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON‐NORDIC LYMPHOMA GROUP PHASE III STUDY by Lugtenburg, P., Nully Brown, P., Holt, B., d'Amore, F., Koene, H., Jongh, E., Fijnheer, R., Loosveld, O., Böhmer, L., Pruijt, H., Verhoef, G., Hoogendoorn, M., Bilgin, Y., Nijland, M., Lam, K., Keizer, B., Jong, D., Zijlstra, J.

Get full text

Multiple B‐cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type‐1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura by LUKEN, B. M., KAIJEN, P. H. P., TURENHOUT, E. A. M., KREMER HOVINGA, J. A., VAN MOURIK, J. A., FIJNHEER, R., VOORBERG, J.

“…Background: The cysteine‐rich/spacer domains of ADAMTS13 contain a major binding site for antibodies in patients with acquired thrombotic thrombocytopenic…”
Get full text

The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission by GROOT, E., FIJNHEER, R., SEBASTIAN, S. A. E., DE GROOT, PH. G., LENTING, P. J.

“…Background: Functional deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura (TTP) patients is associated with circulating ultralarge von Willebrand…”
Get full text

The observation of bleeding complications in haemato-oncological patients: stringent watching, relevant reporting by Ypma, P. F., Kerkhoffs, J.-L. H., van Hilten, J. A., Middelburg, R. A., Coccoris, M., Zwaginga, J. J., Beckers, E. M., Fijnheer, R., van der Meer, P. F., Brand, A.

“…SUMMARY Background The reported percentage of haemato‐oncological patients experiencing bleeding complications is highly variable, ranging from 5 to 70%,…”
Get full text

Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage: associations with cerebral ischaemic events and outcome by Frijns, C J M, Fijnheer, R, Algra, A, van Mourik, J A, van Gijn, J, Rinkel, G J E

“…Objective: To investigate the relation of endothelial cell activation with delayed cerebral ischaemia (DCI) and outcome after subarachnoid haemorrhage (SAH)…”
Get full text

The origin of P-selectin as a circulating plasma protein by Fijnheer, R, Frijns, C J, Korteweg, J, Rommes, H, Peters, J H, Sixma, J J, Nieuwenhuis, H K

“…P-selectin is a 140 kD protein found in the alpha-granules of platelets and the Weibel-Palade bodies of endothelial cells. On cell activation it is expressed…”
Get more information

Risk factors for cystoid macular oedema in patients with uveitis by van Kooij, B, Probst, K, Fijnheer, R, Roest, M, de Loos, W, Rothova, A

“…Purpose To determine ophthalmologic and systemic factors associated with the presence of cystoid macular oedema (CMO) in patients with uveitis. Methods…”
Get full text